Efficacy of preservative-free tafluprost in patients with normal-tension glaucoma previously treated with latanoprost

Abstract

Matteo Sacchi, Edoardo Villani, Paolo NucciUniversity Eye Clinic, San Giuseppe Hospital, University of Milan, Milan, ItalyWe read with interest the article entitled "Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma" by Inoue et al.1 In this study, the authors reported the efficacy of tafluprost in naïve patients with normal-tension glaucoma (NTG) over 3 years of follow-up. The intraocular pressure (IOP)-lowering efficacy of tafluprost in NTG has been recently reported by Mizoguchi et al2 and Nakano et al.3 Whereas tafluprost is available in Europe in a preservative-free formulation, the three aforementioned studies1–3 were all carried out in Japan, where tafluprost is on the market as a benzalkonium chloride (BAK)-containing formulation.View original paper by Inoue and colleagues.